1530.HK vs. 2269.HK

Last updated Apr 3, 2026

Compare and contrast key facts about 3SBio Inc (1530.HK) and WuXi Biologics (2269.HK).

Performance

1530.HK vs. 2269.HK - Performance Comparison

The chart below illustrates the hypothetical performance of a HK$10,000 investment in 3SBio Inc (1530.HK) and WuXi Biologics (2269.HK). The values are adjusted to include any dividend payments, if applicable.

1530.HK vs. 2269.HK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
1530.HK 3SBio Inc	4.96%	300.89%	-15.95%	-8.19%	31.63%	-8.06%	-30.00%	0.60%	-34.29%	49.80%
2269.HK WuXi Biologics	11.26%	78.64%	-40.54%	-50.54%	-35.33%	-9.26%	210.19%	96.71%	14.76%	54.69%

Returns By Period

In the year-to-date period, 1530.HK achieves a 4.96% return, which is significantly lower than 2269.HK's 11.26% return.

1530.HK

• 1D: 0.24%
• 1M: 24.53%
• YTD: 4.96%
• 6M: -17.76%
• 1Y: 97.41%
• 3Y*: 51.38%
• 5Y*: 31.75%
• 10Y*: 10.37%

2269.HK

• 1D: 0.34%
• 1M: -5.46%
• YTD: 11.26%
• 6M: -16.87%
• 1Y: 33.26%
• 3Y*: -9.57%
• 5Y*: -19.75%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

1530.HK vs. 2269.HK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

1530.HK

1530.HK Risk / Return Rank: 80
1530.HK Sharpe Ratio Rank: 78
1530.HK Sortino Ratio Rank: 80
1530.HK Omega Ratio Rank: 75
1530.HK Calmar Ratio Rank: 87
1530.HK Martin Ratio Rank: 83

2269.HK

2269.HK Risk / Return Rank: 60
2269.HK Sharpe Ratio Rank: 62
2269.HK Sortino Ratio Rank: 57
2269.HK Omega Ratio Rank: 58
2269.HK Calmar Ratio Rank: 61
2269.HK Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

1530.HK vs. 2269.HK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 3SBio Inc (1530.HK) and WuXi Biologics (2269.HK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	1530.HK	2269.HK	Difference
Sharpe ratio Return per unit of total volatility	1.25	0.63	+0.62
Sortino ratio Return per unit of downside risk	2.14	1.12	+1.02
Omega ratio Gain probability vs. loss probability	1.26	1.16	+0.10
Calmar ratio Return relative to maximum drawdown	3.54	0.98	+2.56
Martin ratio Return relative to average drawdown	7.68	2.38	+5.30
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

1530.HK vs. 2269.HK - Sharpe Ratio Comparison

The current 1530.HK Sharpe Ratio is 1.25, which is higher than the 2269.HK Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of 1530.HK and 2269.HK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	1530.HK	2269.HK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.25	0.63	+0.62
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.61	-0.30	+0.91
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.21	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.27	-0.05

Correlation

The correlation between 1530.HK and 2269.HK is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

1530.HK vs. 2269.HK - Dividend Comparison

1530.HK's dividend yield for the trailing twelve months is around 0.99%, while 2269.HK has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018
1530.HK 3SBio Inc	0.99%	1.03%	4.11%	1.33%	2.41%	0.00%	0.00%	0.00%	0.68%
2269.HK WuXi Biologics	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

1530.HK vs. 2269.HK - Drawdown Comparison

The maximum 1530.HK drawdown since its inception was -78.63%, smaller than the maximum 2269.HK drawdown of -92.95%. Use the drawdown chart below to compare losses from any high point for 1530.HK and 2269.HK.

Drawdown Indicators

	1530.HK	2269.HK	Difference
Max Drawdown Largest peak-to-trough decline	-78.63%	-92.95%	+14.32%
Max Drawdown (1Y) Largest decline over 1 year	-45.24%	-28.29%	-16.95%
Max Drawdown (5Y) Largest decline over 5 years	-60.61%	-92.95%	+32.34%
Max Drawdown (10Y) Largest decline over 10 years	-78.63%	—	—
Current Drawdown Current decline from peak	-29.30%	-75.98%	+46.68%
Average Drawdown Average peak-to-trough decline	-44.15%	-42.31%	-1.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.88%	14.73%	+6.15%

Volatility

1530.HK vs. 2269.HK - Volatility Comparison

3SBio Inc (1530.HK) has a higher volatility of 23.21% compared to WuXi Biologics (2269.HK) at 14.41%. This indicates that 1530.HK's price experiences larger fluctuations and is considered to be riskier than 2269.HK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	1530.HK	2269.HK	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.21%	14.41%	+8.80%
Volatility (6M) Calculated over the trailing 6-month period	42.90%	31.76%	+11.14%
Volatility (1Y) Calculated over the trailing 1-year period	80.71%	54.68%	+26.03%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	53.82%	66.79%	-12.97%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.89%	60.32%	-10.43%

Financials